Skip to main content
SpringerLink
Log in

Adefovir dipivoxil: an effective treatment option for chronic hepatitis B

  • Drugs and Profile Reports
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table
Table
Fig. 1
Fig
Fig

Notes

  1. 1 The use of tradenames is for product identification purposes only and does not imply endorsement.

References

  1. Dando TM, Plosker, GL. Adefovir dipivoxil: a review of its use in chronic hepatitis B. Drugs 2003; 63 (20): 2215–34.

    Article  PubMed  CAS  Google Scholar 

  2. British National Formulary. No. 46. London: The Pharmaceutical Press, 2003 Sep

  3. Gilead Sciences Inc. Hepsera (adefovir dipivoxil) full prescribing information. Foster City (CA): Gilead Sciences Inc., 2002 Sep

  4. European Agency for Evaluation of Medicinal Products. Hepsera 10mg: summary of product characteristics [online]. Available from URL: http://www.emea.eu.int [Accessed 2003 Dec 5]

  5. Marcellin P, Chang T-T, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003 Feb; 348 (9): 808–16.

    Article  PubMed  CAS  Google Scholar 

  6. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003 Feb; 348 (9): 800–7.

    Article  PubMed  CAS  Google Scholar 

  7. Hadziyannis S, Tassopoulos N, Heathcote J, et al. Two year results from a double-blind, randomized, placebo-controlled study of adefovir dipivoxil (ADV) for presumed precore mutant chronic hepatitis B [oral presentation]. The 38th Annual Meeting of the European Association for the Study of the Liver; 2003 Mar 29–Apr 1; Istanbul

  8. Hadziyannis S, Tassopoulos N, Heathcote J, et al. Two year results from a double-blind, randomized, placebo-controlled study of adefovir dipivoxil (ADV) for presumed precore mutant chronic hepatitis B [abstract no. 492]. J Hepatol 2003 Apr; 38 Suppl. 2: 143

    Article  Google Scholar 

  9. Westland CE, Yang H, Delaney WE IV, et al. Week 48 resistance surveillance in two phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B. Hepatology 2003 Jul; 38 (1): 96–103.

    Article  PubMed  CAS  Google Scholar 

  10. Xiong S, Yang H, Westland CE, et al. Resistance surveillance of HBeAg- chronic hepatitis B (CHB) patients treated for two years with adefovir dipivoxil [abstract]. J Hepatol 2003; 38 Suppl. 2: 182.

    Article  Google Scholar 

  11. Peters M, Hann HW, Martin P, et al. Adefovir dipivoxil (ADV) alone and in combination with lamivudine (LAM) suppresses YMDD mutant hepatitis B virus replication: 48 week preliminary analysis [abstract no. 845]. Hepatology 2002 Oct; 36 (Pt 2): 374A

    Google Scholar 

  12. Willems B, Lau G, Leung N, et al. Safety and efficacy of adding adefovir dipivoxil to lamivudine therapy in compensated chronic hepatitis B patients with YMDD variant HBV and a reduced response to lamivudine: 52-week results [abstract no. 45 plus poster]. Fourth International Workshop Therapies for Viral Hepatitis; 2002 Oct 29–31; Boston

  13. Sung JJY, Lai JY, Zeuzem S, et al. A randomised double-blind phase II study of lamivudine (LAM) compared to lamivudine plus adefovir dipivoxil (ADV) for treatment naive patients with chronic hepatitis B (CHB): week 52 analysis [abstract no. 69]. J Hepatol 2003 Apr; 38 Suppl. 2: 25

    Article  Google Scholar 

  14. Heathcote J, Chang T-T, Lim SG, et al. Safety profile of 48 weeks of adefovir dipivoxil (ADV) 10 mg for the treatment of chronic hepatitis B: an integrated analysis of two phase III studies [abstract no. 1882]. Hepatology 2002 Oct; 36 (Pt 2): 633A

    Google Scholar 

  15. Chang TT, Lim SG, Hadziyannis S, et al. Long-term safety of adefovir dipivoxil (ADV) 10mg once daily for chronic hepatitis B (CHB): an integrated analysis of two phase II studies [abstract no. 454]. J Hepatol 2003 Apr; 38 Suppl. 2: 133

    Article  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Adefovir dipivoxil: an effective treatment option for chronic hepatitis B. Drugs Ther. Perspect 20, 1–4 (2004). https://doi.org/10.2165/00042310-200420040-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200420040-00001

Keywords

Search

Navigation